| BackgroundAllergic rhinitis is a common condition, but many people stillexperience suboptimal control of symptoms despite measure suchas allergen avoidance, intranasal steroids and antihistamines.Allergic-specific immunotherapy (SIT) has been used for almosta century as a desensitizing therapy for allergic diseases andrepresents the only curative and specific method of treatment.ObjectiveTo evaluate the efficacy and safety of the standardized dustmites vaccine for the treatment of allergic rhinitis.MethodsThirty one patients with allergic rhinitis caused by dust miteswere selected in this self-contrast study. Clinical efficacywas evaluated by the symptom and sign scores after sixmonths/two years of specific immunotherapy and compared withthe pretreatment scores .ResultsThirty patients completed the first six months of specificimmunotherapy. A clinically significant reduction in thesymptom and sign scores in these 30 patients comparing withthese of pretreatment was founded, and the difference wassignificant (P<0. 05). Sixteen patients completed the two yearsof specific immunotherapy. A clinically significant reductionin the symptom and sign scores in these 16 patients comparingwith these of treatment after 6 months was founded, and thedifference was significant (P<0. 05). 112 local adversereactions and 9 systemic reactions had occurred in total 876injections, and no fatal systemic reaction occurred.ConclusionStandardized allergen specific immunotherapy is an effectiveand safe treatment in patients suffering from allergic rhinitisdue to dust mites . |
